Annual report pursuant to Section 13 and 15(d)

Fair Value Measurement (Tables)

v2.4.1.9
Fair Value Measurement (Tables)
12 Months Ended
Dec. 31, 2014
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
The following table classifies into the fair value hierarchy, financial instruments measured at fair value on a recurring basis in the accompanying Consolidated Balance Sheets as of December 31, 2014; at December 31, 2013, the Company had no investments at fair value:
 
 
 
Fair Value Measurement as of December 31, 2014
 
($ in thousands)
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Assets
 
 
 
 
 
 
 
 
 
 
 
 
 
Marketable securities:
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S. treasury bills
 
$
19,998
 
$
—
 
$
—
 
$
19,998
 
Mutual funds
 
 
4
 
 
—
 
 
—
 
 
4
 
Total marketable securities
 
 
20,002
 
 
—
 
 
—
 
 
20,002
 
Long-Term Investments, at fair value (1)
 
 
—
 
 
—
 
 
4,160
 
 
4,160
 
Total
 
$
20,002
 
$
—
 
$
4,160
 
$
24,162
 
Schedule of changes in fair value of financial instruments
The table below provides a rollforward of the changes in fair value of Level 3 financial instruments for the year ended December 31, 2014: 
 
 
 
Fair Value of Investments
 
 
 
 
 
 
Short-term
 
Long-term
 
 
 
 
($ in thousands)
 
Other
 
Other
 
CB Pharma
 
Total
 
Balance at December 31, 2013
 
$
—
 
$
—
 
$
—
 
$
—
 
Purchases
 
 
293
 
 
250
 
 
2,675
 
 
3,218
 
Change in fair value of investment
 
 
(293)
 
 
—
 
 
1,235
 
 
942
 
Balance at December 31, 2014
 
$
—
 
$
250
 
$
3,910
 
$
4,160